2-氨基-4H-苯并[d][1,3]噁嗪-4-酮 | 15607-11-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 中文名称: 2-氨基-4H-苯并[d][1,3]噁嗪-4-酮
• 英文名称: 2-amino-benzo[d][1,3]oxazin-4-one
• 英文别名: 2-Imino-1,2-dihydro-4H-<3,1>benzoxazin-4-on；1,2-Dihydro-2-imino-4H-3,1-benzoxazinon-(4)；4-Oxo-2-imino-1,2-dihydro-4H-3,1-benzoxazin；1,2-Dihydro-2-imino-4H-3,1-benzoxazin-4-on；2-Amino-4,5-benzo-6-oxo-1,3-oxazin；2-amino-4H-3,1-benzoxazin-4-one；2-amino-3,1-benzoxazin-4-one
• CAS: 15607-11-1
• 化学式: C₈H₆N₂O₂
• mdl: MFCD08234898
• 分子量: 162.148
• InChiKey: YYPXNAAEYOJYES-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  64.7
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-氨基-4H-苯并[d][1,3]噁嗪-4-酮 在 palladium on activated charcoal 氢气 、 sodium hydride 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 ethyl aminomethylene-(1,2,3,4-tetrahydro-2-oxoquinazolin-4-yl)acetate
  参考文献：
  名称：

  Count, David J. Le, Journal of the Chemical Society. Perkin transactions I, 1983, p. 813 - 816

  摘要：

  DOI：
• 作为产物：
  描述：

  methyl 2-ureidobenzoate 在 硫酸 作用下， 反应 0.33h， 以93%的产率得到2-氨基-4H-苯并[d][1,3]噁嗪-4-酮
  参考文献：
  名称：

  Papadopoulos, E. P.; Torres, C. D., Journal of Heterocyclic Chemistry, 1982, vol. 19, p. 269 - 272

  摘要：

  DOI：

文献信息

• Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions
  申请人：Antel Jochen

  公开号：US20050261292A1

  公开（公告）日：2005-11-24

  The present invention relates to the use of known and novel N-sulfamoyl-N′-arylpiperazines corresponding to Formula I and their physiologically compatible acid addition salts for the treatment or inhibition of obesity and related conditions.

  本发明涉及利用已知和新颖的对应于式I的N-磺酰基-N'-芳基哌嗪及其生理兼容性酸盐，用于治疗或抑制肥胖及相关疾病的用途。
• N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions
  申请人：Antel Jochen

  公开号：US20070149512A1

  公开（公告）日：2007-06-28

  The present invention relates to novel N-sulfamoyl-piperidineamides of Formula I and their physiologically acceptable acid addition salts, to pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment of obesity and its concomitant and/or secondary diseases and related or other conditions.

  本发明涉及具有化学式I的新型N-磺胺基哌啶酰胺及其生理上可接受的酸盐，包括含有它们的药物组合物，其制备方法，以及用于治疗肥胖及其伴随和/或继发疾病以及相关或其他病症的用途。
• REMEDIAL AGENT FOR VIRAL INFECTIOUS DISEASE
  申请人：Asahi Kasei Pharma Corporation

  公开号：EP1403269A1

  公开（公告）日：2004-03-31

  A pyridine ring-containing benzoxazinone derivative or a pharmaceutically acceptable salt or tautomer thereof represented by general formula (1): (wherein R1 to R6 and n are as defined in the description) has excellent inhibitory activity against a protease. Thus, the benzoxazinone derivative or a pharmaceutically acceptable salt thereof is useful as an active ingredient for a therapeutic agent for virus infections, particularly herpes virus infections.

  一种含有吡啶环的苯并噁唑酮衍生物或其药用可接受的盐或互变异构体，由通式（1）表示：（其中R1至R6和n如描述中定义）对蛋白酶具有出色的抑制活性。因此，该苯并噁唑酮衍生物或其药用可接受的盐可作为抗病毒治疗剂的活性成分，特别是对疱疹病毒感染。
• N-sulfamoyl-N'-benzopyranpiperidine compounds and uses thereof
  申请人：Antel Jochen

  公开号：US20070117823A1

  公开（公告）日：2007-05-24

  N-sulfamoyl-N′-benzopyranpiperidine compounds of formula I and their physiologically acceptable acid addition salts, pharmaceutical compositions comprising them, processes for their preparation, and their use for the treatment and/or inhibition of glaucoma, epilepsy, bipolar disorders, migraine, neuropathic pain, obesity, type II diabetes, metabolic syndrome, alcohol dependence, and/or cancer, and related concomitant and/or secondary diseases or conditions.

  式I的N-磺胺基-N'-苯并吡啶啉化合物及其生理上可接受的酸盐，包含它们的药物组合物，其制备方法，以及它们用于治疗和/或抑制青光眼、癫痫、双相情感障碍、偏头痛、神经痛、肥胖症、2型糖尿病、代谢综合征、酒精依赖症和/或癌症的用途，以及相关的并发和/或继发疾病或症状。
• Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
  申请人：Antel Jochen

  公开号：US20050124660A1

  公开（公告）日：2005-06-09

  The present invention relates to a novel medical use of compounds with CB 1 -receptor activity selected from the group of 4,5-dihydro-1H-pyrazole derivatives, 1H-Imidazole derivatives, thiazole derivatives and/or 1H-1,2,4-triazole-3-carboxamide derivatives, as each defined in the specification, or of a prodrug thereof, a tautomer thereof or a salt thereof, in the manufacture of medicaments for the treatment and/or prophylaxis of CB 1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile, as well as in adolescent, patients. Furthermore, the invention pertains to the use of said compounds with CB 1 -receptor activity in combination with lipase inhibitors. Said compounds are particularly suitable in combination with lipase inhibitors in the manufacture of medicaments for the treatment and/or prophylaxis of obesity in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. Preferred lipase inhibitors are orlistat, panclicins, ATL-962 and/or lipstatin.

  本发明涉及一种新型医用化合物，该化合物具有CB1受体活性，所述化合物选自4,5-二氢-1H-吡唑衍生物、1H-咪唑衍生物、噻唑衍生物和/或1H-1,2,4-三唑-3-羧酰胺衍生物，如规范中所定义，或其前药、互变异构体或盐，用于制造治疗和/或预防CB1受体相关疾病的药物，适用于青少年患者，以及用于治疗和/或预防青少年和/或成年患者的药物诱导肥胖症。此外，本发明涉及将具有CB1受体活性的化合物与脂肪酶抑制剂结合使用。这些化合物与脂肪酶抑制剂结合使用特别适用于制造用于治疗和/或预防青少年或儿童患者的肥胖症的药物，以及用于治疗和/或预防青少年和/或成年患者的药物诱导肥胖症。优选的脂肪酶抑制剂是奥利司他、泛克立汀、ATL-962和/或脂肪酸盐酶抑制剂。